---
title: "12 Health Care Stocks Moving In Monday's Intraday Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289813264.md"
description: "During Monday's intraday session, several healthcare stocks experienced significant volatility. Regentis Biomaterials surged 370.7% to $7.06, while Cuprina Holdings rose 133.12%. Other gainers included QTREX Quantum, Gelteq, Cypherpunk Technologies, and SAB Biotherapeutics. Conversely, Elicio Therapeutics plummeted 72.1%, followed by Context Therapeutics down 49.93% and Neumora Therapeutics falling 48.32%. Additional decliners were 20/20 Biolabs, Traws Pharma, and Genprex."
datetime: "2026-06-15T17:05:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289813264.md)
  - [en](https://longbridge.com/en/news/289813264.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289813264.md)
---

# 12 Health Care Stocks Moving In Monday's Intraday Session

### Gainers

-   **Regentis Biomaterials** (AMEX:RGNT) stock rose 370.7% to $7.06 during Monday's regular session. The market value of their outstanding shares is at $7.7 million.
-   **Cuprina Holdings (Cayman)** (NASDAQ:CUPR) stock rose 133.12% to $9.26. The market value of their outstanding shares is at $10.6 million.
-   **QTREX Quantum** (NASDAQ:QTEX) shares increased by 67.31% to $2.16. The market value of their outstanding shares is at $58.3 million.
-   **Gelteq** (NASDAQ:GELS) shares rose 29.29% to $1.28. The company's market cap stands at $10.6 million.
-   **Cypherpunk Technologies** (NASDAQ:CYPH) stock moved upwards by 25.66% to $0.82. The market value of their outstanding shares is at $69.2 million.
-   **SAB Biotherapeutics** (NASDAQ:SABS) shares rose 22.82% to $4.09. The company's market cap stands at $254.6 million.

### Losers

-   **Elicio Therapeutics** (NASDAQ:ELTX) stock fell 72.1% to $4.15 during Monday's regular session. The company's market cap stands at $283.4 million.
-   **Context Therapeutics** (NASDAQ:CNTX) stock decreased by 49.93% to $0.7. The company's market cap stands at $127.7 million.
-   **Neumora Therapeutics** (NASDAQ:NMRA) stock declined by 48.32% to $0.92. The market value of their outstanding shares is at $329.8 million.
-   **20/20 Biolabs** (NASDAQ:AIDX) stock fell 34.74% to $0.63. The market value of their outstanding shares is at $10.2 million.
-   **Traws Pharma** (NASDAQ:TRAW) shares declined by 27.04% to $0.93. The company's market cap stands at $19.3 million.
-   **Genprex** (NASDAQ:GNPX) stock fell 23.62% to $0.49. The company's market cap stands at $6.9 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [CYPH.US](https://longbridge.com/en/quote/CYPH.US.md)
- [GNPX.US](https://longbridge.com/en/quote/GNPX.US.md)
- [TRAW.US](https://longbridge.com/en/quote/TRAW.US.md)
- [CNTX.US](https://longbridge.com/en/quote/CNTX.US.md)
- [QTEX.US](https://longbridge.com/en/quote/QTEX.US.md)
- [RGNT.US](https://longbridge.com/en/quote/RGNT.US.md)
- [SABS.US](https://longbridge.com/en/quote/SABS.US.md)
- [CUPR.US](https://longbridge.com/en/quote/CUPR.US.md)
- [GELS.US](https://longbridge.com/en/quote/GELS.US.md)
- [AIDX.US](https://longbridge.com/en/quote/AIDX.US.md)
- [NMRA.US](https://longbridge.com/en/quote/NMRA.US.md)
- [ELTX.US](https://longbridge.com/en/quote/ELTX.US.md)
- [SABSW.US](https://longbridge.com/en/quote/SABSW.US.md)

## Related News & Research

- [Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement | RGNT Stock News](https://longbridge.com/en/news/290122846.md)
- [Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug](https://longbridge.com/en/news/290083011.md)
- [QTREX Quantum stock rallies as its AME system enters commercial production](https://longbridge.com/en/news/289795534.md)
- [Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail](https://longbridge.com/en/news/289813061.md)
- [CNTX: CTIM-76 achieved a 29% response rate and low-grade CRS in late-line ovarian cancer patients](https://longbridge.com/en/news/289805735.md)